新发与恶化慢性心衰中托拉塞米与呋塞米的比较:TRANSFORM-HF 亚组分析
该研究为 TRANSFORM-HF 随机试验的事后分析,纳入 2858 例有射血分数记录的心衰住院患者,比较新发心衰与恶化慢性心衰的临床特征及托拉塞米 vs 呋塞米的 12 个月结局。新发心衰患者更年轻、肾功能更好、利钠肽水平更低,12 个月全因死亡率和再住院率更低,KCCQ-CSS 改善更显著;无论心衰类型,托拉塞米与呋塞米在死亡、住院和患者报告结局上均无显著差异。
要点
- 新发心衰患者 12 个月全因死亡率 9.1%,显著低于恶化慢性心衰的 25.4%(aHR 0.50)。
- 新发心衰患者 12 个月 KCCQ-CSS 改善更显著(调整均数差 6.26)。
- 无论新发或恶化慢性心衰,托拉塞米与呋塞米在死亡和住院结局上无显著差异。
核心结论
- 新发心衰患者相比恶化慢性心衰患者具有更好的临床和患者报告结局。
- 无论心衰类型,托拉塞米与呋塞米在 12 个月临床或患者报告结局上无显著差异。
研究设计与样本
- TRANSFORM-HF 随机临床试验的事后分析,纳入 2858 例有射血分数记录的心衰住院患者。
- 研究于 2022 年 6 月 18 日至 2022 年 3 月进行(原文如此),数据分析于 2023 年 3 月至 5 月。
- 患者按心衰类型(新发 vs 恶化慢性)和袢利尿剂策略(托拉塞米 vs 呋塞米)分组。
主要发现
- 新发心衰患者 838 例(29.3%),恶化慢性心衰患者 2020 例(70.7%)。
- 新发心衰患者更年轻(平均 60.6 岁 vs 66.1 岁),肾小球滤过率更高(平均 68.6 vs 57.0),BNP 中位数更低(855.0 pg/mL vs 1022.0 pg/mL)。
临床怎么用
- 临床中应识别新发心衰与恶化慢性心衰的不同预后特征,新发心衰患者预后相对较好。
- 选择托拉塞米或呋塞米时,无需基于心衰类型(新发 vs 恶化慢性)进行区分。
局限性
- 本研究为 TRANSFORM-HF 试验的事后亚组分析,结果需谨慎解读。
- 仅纳入有射血分数记录的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Differences in clinical profiles, outcomes, and diuretic treatment effects may exist between patients with de novo heart failure (HF) and worsening chronic HF (WHF). OBJECTIVES: To compare clinical characteristics and treatment outcomes of torsemide vs furosemide in patients hospitalized with de novo HF vs WHF. DESIGN, SETTING, AND PARTICIPANTS: All patients with a documented ejection fraction who were randomized in the Torsemide Comparison With Furosemide for Management of Heart Failure (TRANSFORM-HF) trial, conducted from June 18 through March 2022, were included in this post hoc analysis. Study data were analyzed March to May 2023. EXPOSURE: Patients were categorized by HF type and further divided by loop diuretic strategy. MAIN OUTCOMES AND MEASURES: End points included all-cause mortality and hospitalization outcomes over 12 months, as well as change from baseline in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS). RESULTS: Among 2858 patients (mean [SD] age, 64.5 [14.0] years; 1803 male [63.1%]), 838 patients (29.3%) had de novo HF, and 2020 patients (70.7%) had WHF. Patients with de novo HF were younger (mean [SD] age, 60.6 [14.5] years vs 66.1 [13.5] years), had a higher glomerular filtration rate (mean [SD], 68.6 [24.9] vs 57.0 [24.0]), lower levels of natriuretic peptides (median [IQR], brain-type natriuretic peptide, 855.0 [423.0-1555.0] pg/mL vs 1022.0 [500.0-1927.0] pg/mL), and tended to be discharged on lower doses of loop diuretic (mean [SD], 50.3 [46.2] mg vs 63.8 [52.4] mg). De novo HF was associated with lower all-cause mortality at 12 months (de novo, 65 of 838 [9.1%] vs WHF, 408 of 2020 [25.4%]; adjusted hazard ratio [aHR], 0.50; 95% CI, 0.38-0.66; P < .001). Similarly, lower all-cause first rehospitalization at 12 months and greater improvement from baseline in KCCQ-CSS at 12 months were noted among patients with de novo HF (median [IQR]: de novo, 29.94 [27.35-32.54] vs WHF, 23.68 [21.62-25.74]; adjusted estimated difference in means: 6.26; 95% CI, 3.72-8.81; P < .001). There was no significant difference in mortality with torsemide vs furosemide in either de novo (No. of events [rate per 100 patient-years]: torsemide, 27 [7.4%] vs furosemide, 38 [10.9%]; aHR, 0.70; 95% CI, 0.40-1.14; P = .15) or WHF (torsemide 212 [26.8%] vs furosemide, 196 [24.0%]; aHR, 1.08; 95% CI, 0.89-1.32; P = .42; P for interaction = .10), In addition, no significant differences in hospitalizations, first all-cause hospitalization, or total hospitalizations at 12 months were noted with a strategy of torsemide vs furosemide in either de novo HF or WHF. CONCLUSIONS AND RELEVANCE: Among patients discharged after hospitalization for HF, de novo HF was associated with better clinical and patient-reported outcomes when compared with WHF. Regardless of HF type, there was no significant difference between torsemide and furosemide with respect to 12-month clinical or patient-reported outcomes.
引用
- Krim, Anand, Greene, et al. Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 37955908. doi:10.1001/jamacardio.2023.4776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。